ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) BEYOND LDLR TARGETING: FOCUS ON GLUCOSE METABOLISM

被引：0
|
作者：
Balzarotti, Gloria [1 ]
Tibolla, Gianpaolo [1 ]
Ruscica, Massimiliano [1 ]
Di Cairano, Eliana [1 ]
Perego, Carla [1 ]
Catapano, Alberico Luigi [1 ,3 ]
Norata, Giuseppe Danilo [1 ,2 ]
机构：
[1] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[2] Bassini Hosp, Sisa Ctr, Milan, Italy
[3] Irccs Multimed, Milan, Italy
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.332
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG204
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [41] IDENTIFICATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FROM NATURAL PRODUCTS
    Hirata, Hiroshi
    Kontani, Ami
    Takazumi, Koji
    Segawa, Shuichi
    Tsuchiya, Youichi
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 1175 - 1175
  • [42] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
    Joseph, Lee
    Robinson, Jennifer G.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2015, 58 (01) : 19 - 31
  • [43] Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
    Sharotri, Vikas
    Collier, Daniel M.
    Olson, Diane R.
    Zhou, Ruifeng
    Snyder, Peter M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) : 19266 - 19274
  • [44] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia
    Awan, Zuhier
    Baass, Alexis
    Genest, Jacques
    CLINICAL CHEMISTRY, 2014, 60 (11) : 1380 - 1389
  • [45] Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
    Patel, Jeenal
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (04): : S76 - S82
  • [46] The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
    Marston, Nicholas A.
    Gurmu, Yared
    Melloni, Giorgio E. M.
    Bonaca, Marc
    Gencer, Baris
    Sever, Peter S.
    Pedersen, Terje R.
    Keech, Anthony C.
    Roselli, Carolina
    Lubitz, Steven A.
    Ellinor, Patrick T.
    O'Donoghue, Michelle L.
    Giugliano, Robert P.
    Ruff, Christian T.
    Sabatine, Marc S.
    CIRCULATION, 2020, 141 (20) : 1600 - 1607
  • [47] The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
    Ben Zadok, O. Itzhaki
    Mager, A.
    Leshem-Lev, D.
    Lev, E.
    Kornowski, R.
    Eisen, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1828 - 1828
  • [48] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Huimin Sun
    Wen Meng
    Jie Zhu
    Lu Wang
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 643 - 658
  • [49] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons
    Yadav, K.
    Sharma, M.
    Ferdinand, K. C.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (10) : 853 - 862
  • [50] Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia
    Robinson, Jennifer G.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2016, 59 (02) : 165 - 171
12345